Last Updated: November 16, 2026

Details for Patent: 10,292,954

« Back to Dashboard


Which drugs does patent 10,292,954 protect, and when does it expire?

Patent 10,292,954 protects SOHONOS and is included in one NDA.

This patent has thirty-one patent family members in nineteen countries.

Summary for Patent: 10,292,954
Title:Composition and method for muscle repair and regeneration
Abstract:The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Inventor(s):Masahiro Iwamoto, Maurizio Pacifici
Assignee: Thomas Jefferson University
Application Number:US15/674,357
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,292,954

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-001 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-002 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-003 Aug 16, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-004 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,292,954

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011296080 ⤷  Start Trial
Brazil 112013004685 ⤷  Start Trial
Canada 2809374 ⤷  Start Trial
Chile 2013000580 ⤷  Start Trial
China 103200937 ⤷  Start Trial
China 111773213 ⤷  Start Trial
Colombia 6680694 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.